As previously reported, Canaccord initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $10 price target telling investors that the firm expects positive data during Q1 0f 2026 for the company’s lead asset tovecimig in second-line biliary tract carcinoma. Compass also has two additional assets in the clinic, both of which have shown activity in solid tumors, potentially diversifying revenues long term, the analyst added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Compass Therapeutics initiated with a Buy at Canaccord
- Compass Therapeutics initiated with an Outperform at Citizens JMP
- Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
- Compass Therapeutics Reports Q3 2025 Financial Results